Skip to main content
Top
Published in: Cancer Cell International 1/2006

Open Access 01-12-2006 | Primary research

Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells

Authors: Mostafa K El Awady, Noha G Badr El Din, Wael T El Garf, Samar S Youssef, Moataza H Omran, Jasmin El Abd, Said A Goueli

Published in: Cancer Cell International | Issue 1/2006

Login to get access

Abstract

Background

Hepatitis C (HCV) viral infection is a serious medical problem in Egypt and it has a devastating impact on the Egyptian economy. It is estimated that over 15% of Egyptians are infected by the virus and thus finding a cure for this disease is of utmost importance. Current therapies for hepatitis C virus (HCV) genotype 4 with interferon/ribavirin have not been successful and thus the development of alternative therapy for this genotype is disparately needed.

Results

Although previous studies utilizing viral subgenomic or full cDNA fragments linked to reporter genes transfected into adhered cells or in a cell free system showed promise, demonstration of efficient viral replication was lacking. Thus, we utilized HepG2 cells infected with native HCV RNA genomes in a replication competent system and used antisense phosphorothioate Oligonucleotides (S-ODN) against stem loop IIId and the AUG translation start site of the viral polyprotein precursor to monitor viral replication. We were able to show complete arrest of intracellular replication of HCV-4 at 1 uM S-ODN, thus providing a proof of concept for the potential antiviral activity of S-ODN on native genomic replication of HCV genotype 4.

Conclusion

We have successfully demonstrated that by using two S-ODNs [(S-ODN1 (nt 326–348) and S-ODN-2 (nt 264–282)], we were able to completely inhibit viral replication in culture, thus confirming earlier reports on subgenomic constructs and suggesting a potential therapeutic value in HCV type 4.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoofingale JH: Hepatitis C-the clinical spectrum of disease. Hepatology. 1997, 26: S15-S20. 10.1002/hep.510260703.CrossRef Hoofingale JH: Hepatitis C-the clinical spectrum of disease. Hepatology. 1997, 26: S15-S20. 10.1002/hep.510260703.CrossRef
2.
go back to reference Willems M, Metselaar HJ, Tilanus HW, Schelm SW, deMan RA: Liver transplantation and hepatitis C. Transplant Int. 2002, 15: 61-72. 10.1111/j.1432-2277.2002.tb00132.x.CrossRef Willems M, Metselaar HJ, Tilanus HW, Schelm SW, deMan RA: Liver transplantation and hepatitis C. Transplant Int. 2002, 15: 61-72. 10.1111/j.1432-2277.2002.tb00132.x.CrossRef
3.
go back to reference Scott LJ, Perry CM: Interferon a2b plus ribavirin- a review of its use in the treatment of chronic hepatitis C. Drugs. 2002, 62: 507-556. 10.2165/00003495-200262030-00009.CrossRefPubMed Scott LJ, Perry CM: Interferon a2b plus ribavirin- a review of its use in the treatment of chronic hepatitis C. Drugs. 2002, 62: 507-556. 10.2165/00003495-200262030-00009.CrossRefPubMed
4.
go back to reference Tan S-L, Pause A, Shi Y, Sonenberg N: Hepatitis C therapeutics: current status and emerging strategies. Nature Rev Drug Discovery. 2002, 1: 867-881. 10.1038/nrd937.CrossRef Tan S-L, Pause A, Shi Y, Sonenberg N: Hepatitis C therapeutics: current status and emerging strategies. Nature Rev Drug Discovery. 2002, 1: 867-881. 10.1038/nrd937.CrossRef
5.
go back to reference Manns MP: PEG-interferon-α2b plus ribavirin compared with interferon- α 2b plus ribavirin for initial treatment of chronic hepatitis: a randomized trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.CrossRefPubMed Manns MP: PEG-interferon-α2b plus ribavirin compared with interferon- α 2b plus ribavirin for initial treatment of chronic hepatitis: a randomized trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.CrossRefPubMed
6.
go back to reference Crooke ST: Progress in antisense technology. Ann Rev Med. 2004, 55: 61-95. 10.1146/annurev.med.55.091902.104408.CrossRefPubMed Crooke ST: Progress in antisense technology. Ann Rev Med. 2004, 55: 61-95. 10.1146/annurev.med.55.091902.104408.CrossRefPubMed
7.
go back to reference Dasgupta A, Das S, Izumi R, Venkatesan A, Barat B: Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiology Letters. 2004, 234: 189-199.PubMed Dasgupta A, Das S, Izumi R, Venkatesan A, Barat B: Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiology Letters. 2004, 234: 189-199.PubMed
8.
go back to reference Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WHO: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothionate oligonucleotides. Hepatology. 1995, 22: 707-717. 10.1016/0270-9139(95)90287-2.PubMed Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WHO: Specific inhibition of hepatitis C viral gene expression by antisense phosphorothionate oligonucleotides. Hepatology. 1995, 22: 707-717. 10.1016/0270-9139(95)90287-2.PubMed
9.
go back to reference Bartenschlager R: In vitro models for hepatitis C. Viral Research. 2002, 82: 25-32. 10.1016/S0168-1702(01)00383-5.CrossRef Bartenschlager R: In vitro models for hepatitis C. Viral Research. 2002, 82: 25-32. 10.1016/S0168-1702(01)00383-5.CrossRef
10.
go back to reference El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Gad YZ, Omran M, Mohamed SA: Prediction of relapse after interferon therapy in HCV infection by use of triple assay. Journal of Gastroenterology and Hepatology. El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Gad YZ, Omran M, Mohamed SA: Prediction of relapse after interferon therapy in HCV infection by use of triple assay. Journal of Gastroenterology and Hepatology.
11.
go back to reference Hanecak R, Brown-Driver V, Maureen CF: Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. Hepatology. 1996, 70: 5203-5212. Hanecak R, Brown-Driver V, Maureen CF: Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. Hepatology. 1996, 70: 5203-5212.
12.
go back to reference Ohno O, Mizokami M, Wu RR: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997, 35: 201-7.PubMedCentralPubMed Ohno O, Mizokami M, Wu RR: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997, 35: 201-7.PubMedCentralPubMed
13.
go back to reference Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM: Detection of replicative intermediate of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest. 1991, 88: 1058-60.PubMedCentralCrossRefPubMed Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM: Detection of replicative intermediate of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest. 1991, 88: 1058-60.PubMedCentralCrossRefPubMed
14.
go back to reference Martell M, Gomez J, Esteban JI: High throughput real-time reverse transcription-PCR quantitation of Hepatitis C virus RNA. J Clin Microbiology. 1999, 37: 327-332. Martell M, Gomez J, Esteban JI: High throughput real-time reverse transcription-PCR quantitation of Hepatitis C virus RNA. J Clin Microbiology. 1999, 37: 327-332.
15.
go back to reference Imanishi T, Obika S: Down-regulation of a gene expression by an antisense BNA oligonucleotide. Nippon Yakurigaku Zasshi. 2002, 120: 85-90.CrossRefPubMed Imanishi T, Obika S: Down-regulation of a gene expression by an antisense BNA oligonucleotide. Nippon Yakurigaku Zasshi. 2002, 120: 85-90.CrossRefPubMed
16.
go back to reference McHutchison JG, Patel K: Future therapy of Hepatitis C. Hepatology. 2002, 36 (Suppl): 245-252. 10.1002/hep.1840360731.CrossRef McHutchison JG, Patel K: Future therapy of Hepatitis C. Hepatology. 2002, 36 (Suppl): 245-252. 10.1002/hep.1840360731.CrossRef
17.
go back to reference Cornberg M, Wedemeyer H, Manns MP: Hepatitis C: Therapeutic perspectives. Forum (Genova). 2001, 11: 154-62. Cornberg M, Wedemeyer H, Manns MP: Hepatitis C: Therapeutic perspectives. Forum (Genova). 2001, 11: 154-62.
18.
go back to reference Heintges T, Encke J, zu Putlitz J, Wands JR: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol. 2001, 64: 671-680. 10.1002/jmv.2089.CrossRef Heintges T, Encke J, zu Putlitz J, Wands JR: Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor. J Med Virol. 2001, 64: 671-680. 10.1002/jmv.2089.CrossRef
19.
go back to reference Stefanie Seipp, Muller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T: Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol. 1997, 78: 2467-2476.CrossRef Stefanie Seipp, Muller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T: Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol. 1997, 78: 2467-2476.CrossRef
20.
go back to reference Dash S, Halim A, Tsuji H, Hiramatsu N, Gerber MA: Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathology. 1997, 151: 363-373. Dash S, Halim A, Tsuji H, Hiramatsu N, Gerber MA: Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathology. 1997, 151: 363-373.
21.
go back to reference Takehara T, Hayashi N, Miaymoto Y, Yamamoto M, Mita E, Fusamoto H, Kamada T: Expression of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. Hepatology. 1995, 21: 746-751. 10.1016/0270-9139(95)90528-6.PubMed Takehara T, Hayashi N, Miaymoto Y, Yamamoto M, Mita E, Fusamoto H, Kamada T: Expression of the hepatitis C virus genome in rat liver after cationic liposome-mediated in vivo gene transfer. Hepatology. 1995, 21: 746-751. 10.1016/0270-9139(95)90528-6.PubMed
22.
go back to reference Ito T, Yasui K, Mukaigawa J, Katsume A, Kohara M, Mitamura K: Acquisition of susceptibility to hepatitis C virus replication in HepG2 cells by fusion with primary human hepatocytes: establishment of a quantitative assay for hepatitis C virus infectivity in a cell culture system. Hepatology. 2001, 34: 566-72. 10.1053/jhep.2001.26752.CrossRefPubMed Ito T, Yasui K, Mukaigawa J, Katsume A, Kohara M, Mitamura K: Acquisition of susceptibility to hepatitis C virus replication in HepG2 cells by fusion with primary human hepatocytes: establishment of a quantitative assay for hepatitis C virus infectivity in a cell culture system. Hepatology. 2001, 34: 566-72. 10.1053/jhep.2001.26752.CrossRefPubMed
23.
go back to reference de Diesbach P, Berens C, N'Kuli F: Identification, purification and partial characterization of an oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acid Research. 2000, 28: 868-874. 10.1093/nar/28.4.868.CrossRef de Diesbach P, Berens C, N'Kuli F: Identification, purification and partial characterization of an oligonucleotide receptor in membranes of HepG2 cells. Nucleic Acid Research. 2000, 28: 868-874. 10.1093/nar/28.4.868.CrossRef
24.
go back to reference Wu CH, Wu GY: Targeted inhibition of hepatitis C virus- directed gene expression in human hepatoma cell lines. Gastroenterology. 1998, 11: 1304-1312. 10.1016/S0016-5085(98)70437-8.CrossRef Wu CH, Wu GY: Targeted inhibition of hepatitis C virus- directed gene expression in human hepatoma cell lines. Gastroenterology. 1998, 11: 1304-1312. 10.1016/S0016-5085(98)70437-8.CrossRef
25.
go back to reference Bacaniello VR, Baltimore D: Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981, 214: 916-919.CrossRef Bacaniello VR, Baltimore D: Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981, 214: 916-919.CrossRef
26.
go back to reference Bergmann M, Garcia-Sastre A, Palese P: Transfection mediated recombination of Influenza A virus. J Virology. 1992, 66: 7576-780.PubMedCentralPubMed Bergmann M, Garcia-Sastre A, Palese P: Transfection mediated recombination of Influenza A virus. J Virology. 1992, 66: 7576-780.PubMedCentralPubMed
27.
go back to reference Schuster C, Isel C, Imbert I, Ehresmann C, Marquet R, Kieny MP: Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA. J Virology. 2002, 76: 8058-68. 10.1128/JVI.76.16.8058-8068.2002.PubMedCentralCrossRefPubMed Schuster C, Isel C, Imbert I, Ehresmann C, Marquet R, Kieny MP: Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA. J Virology. 2002, 76: 8058-68. 10.1128/JVI.76.16.8058-8068.2002.PubMedCentralCrossRefPubMed
28.
go back to reference Smith RM, Walton CM, Wu CH, Wu GY: Secondary structure and hybridization accessibility of hepatitis C virus 3'- terminal sequences. J Virology. 2002, 76: 9563-74. 10.1128/JVI.76.19.9563-9574.2002.PubMedCentralCrossRefPubMed Smith RM, Walton CM, Wu CH, Wu GY: Secondary structure and hybridization accessibility of hepatitis C virus 3'- terminal sequences. J Virology. 2002, 76: 9563-74. 10.1128/JVI.76.19.9563-9574.2002.PubMedCentralCrossRefPubMed
29.
go back to reference McCaffrey AP, Ohashi K, Meuse L: Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther. 2002, 5: 676-84. 10.1006/mthe.2002.0600.CrossRefPubMed McCaffrey AP, Ohashi K, Meuse L: Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther. 2002, 5: 676-84. 10.1006/mthe.2002.0600.CrossRefPubMed
30.
go back to reference Ito T, Lai MMC: Determination of the secondary structure of and cellular protein binding to the 3'-untranslated region of the hepatitis C virus RNA genome. J Virology. 1997, 71: 8698-706.PubMedCentralPubMed Ito T, Lai MMC: Determination of the secondary structure of and cellular protein binding to the 3'-untranslated region of the hepatitis C virus RNA genome. J Virology. 1997, 71: 8698-706.PubMedCentralPubMed
31.
go back to reference Tsuchihara K, Tanaka T, Hijikata M: Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X. J Virology. 1997, 71: 6720-26.PubMedCentralPubMed Tsuchihara K, Tanaka T, Hijikata M: Specific interaction of polypyrimidine tract-binding protein with the extreme 3'-terminal structure of the hepatitis C virus genome, the 3'X. J Virology. 1997, 71: 6720-26.PubMedCentralPubMed
32.
go back to reference Brown EA, Zhang H, Ping LH, Lemon SM: Secondary structure of the 5' non-translated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res. 1992, 20: 5041-45.PubMedCentralCrossRefPubMed Brown EA, Zhang H, Ping LH, Lemon SM: Secondary structure of the 5' non-translated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res. 1992, 20: 5041-45.PubMedCentralCrossRefPubMed
33.
go back to reference Jubin R, Vantuno NE, Kieft JS: Hepatitis C virus Internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. J Virology. 2000, 74: 10430-37. 10.1128/JVI.74.22.10430-10437.2000.PubMedCentralCrossRefPubMed Jubin R, Vantuno NE, Kieft JS: Hepatitis C virus Internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. J Virology. 2000, 74: 10430-37. 10.1128/JVI.74.22.10430-10437.2000.PubMedCentralCrossRefPubMed
34.
go back to reference Radhakrishnan SK, Layden TJ, Gartel AL: RNA interference as a new strategy against viral hepatitis. Virology. 2004, 323: 173-181. 10.1016/j.virol.2004.02.021.CrossRefPubMed Radhakrishnan SK, Layden TJ, Gartel AL: RNA interference as a new strategy against viral hepatitis. Virology. 2004, 323: 173-181. 10.1016/j.virol.2004.02.021.CrossRefPubMed
35.
go back to reference Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNA in cell culture by small interfering RNAs. Proc Natl Acad Sci USA. 2003, 100: 235-240. 10.1073/pnas.0235524100.PubMedCentralCrossRefPubMed Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNA in cell culture by small interfering RNAs. Proc Natl Acad Sci USA. 2003, 100: 235-240. 10.1073/pnas.0235524100.PubMedCentralCrossRefPubMed
36.
go back to reference Paroo Z, Corey DR: Challenges for RNAi in vivo. Trends in Biotechnology. 2004, 22: 390-394. 10.1016/j.tibtech.2004.06.004.CrossRefPubMed Paroo Z, Corey DR: Challenges for RNAi in vivo. Trends in Biotechnology. 2004, 22: 390-394. 10.1016/j.tibtech.2004.06.004.CrossRefPubMed
37.
go back to reference Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL: Cellular Uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem. 2004, 15: 290-299. 10.1021/bc034221g.CrossRefPubMed Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL: Cellular Uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem. 2004, 15: 290-299. 10.1021/bc034221g.CrossRefPubMed
38.
go back to reference Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem. 2002, 277: 8741-8748. 10.1074/jbc.M108459200.CrossRefPubMed Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem. 2002, 277: 8741-8748. 10.1074/jbc.M108459200.CrossRefPubMed
Metadata
Title
Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells
Authors
Mostafa K El Awady
Noha G Badr El Din
Wael T El Garf
Samar S Youssef
Moataza H Omran
Jasmin El Abd
Said A Goueli
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2006
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-6-18

Other articles of this Issue 1/2006

Cancer Cell International 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine